One cause of cancer mortality is tumor evolution to therapy-resistant disease. First line therapy often targets the dominant clone, and drug resistance can emerge from preexisting clones that gain fitness through therapy-induced natural selection. Such mutations may be identified using targeted sequencing assays by analysis of noise in high-depth data. Here, we develop a comprehensive, unbiased model for sequencing error background. We find that noise in sufficiently deep DNA sequencing data can be approximated by aggregating negative binomial distributions. Mutations with frequencies above noise may have prognostic value. We evaluate our model with simulated exponentially expanded populations as well as data from cell line and patient sample dilution experiments, demonstrating its utility in prognosticating tumor progression. Our results may have the potential to identify significant mutations that can cause recurrence. These results are relevant in the pre-treatment clinical setting to determine appropriate therapy and prepare for potential recurrence pretreatment.
Keywords: 02.50.-r; 87.18.Tt; 87.23.Kg.
Overview of resistance to systemic therapy in patients with breast cancer.Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1. Adv Exp Med Biol. 2007. PMID: 17993229 Review.
MERIT reveals the impact of genomic context on sequencing error rate in ultra-deep applications.BMC Bioinformatics. 2018 Jun 8;19(1):219. doi: 10.1186/s12859-018-2223-1. BMC Bioinformatics. 2018. PMID: 29884116 Free PMC article.
Persistence and selection of an expanded B-cell clone in the setting of rituximab therapy for Sjögren's syndrome.Arthritis Res Ther. 2014 Feb 11;16(1):R51. doi: 10.1186/ar4481. Arthritis Res Ther. 2014. PMID: 24517398 Free PMC article. Clinical Trial.
Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma.J Hepatol. 2017 Aug;67(2):293-301. doi: 10.1016/j.jhep.2017.03.005. Epub 2017 Mar 18. J Hepatol. 2017. PMID: 28323123
Clonal evolution of acute myeloid leukemia highlighted by latest genome sequencing studies.Oncotarget. 2016 Sep 6;7(36):58586-58594. doi: 10.18632/oncotarget.10850. Oncotarget. 2016. PMID: 27474172 Free PMC article. Review.
Cited by 2 articles
Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia.Blood. 2020 Mar 19;135(12):921-933. doi: 10.1182/blood.2019002499. Blood. 2020. PMID: 31971569
Association of JAK2-V617F Mutations Detected by Solid Tumor Sequencing With Coexistent Myeloproliferative Neoplasms.JAMA Oncol. 2019 Feb 1;5(2):265-267. doi: 10.1001/jamaoncol.2018.6286. JAMA Oncol. 2019. PMID: 30605212 Free PMC article.